Mevidalen (
LY3154207) is a positive allosteric modulator of the
dopamine D1 receptor that enhances the affinity of
dopamine for the D1 receptor. The safety, tolerability, motor effects, and pharmacokinetics of
mevidalen were studied in patients with
Parkinson disease.
Mevidalen or placebo was given once daily for 14 days to 2 cohorts of patients (cohort 1, 75 mg; cohort 2, titration from 15 to 75 mg). For both cohorts, the median time to maximum concentration for
mevidalen plasma concentration was about 2 hours, the apparent steady-state clearance was 20-25 L/h, and
mevidalen plasma concentrations were similar between the 1st and 14th administration in cohort 1, indicating minimal accumulation upon repeated dosing.
Mevidalen was well tolerated, and most treatment-emergent adverse events were mild. Blood pressure and pulse rate increased when taking
mevidalen, but there was considerable overlap with patients taking placebo, and vital signs normalized with repeated dosing. In the
Movement Disorder Society-United
Parkinson's Disease Rating Scale, all patients taking
mevidalen showed a better motor examination sub-score on day 6 compared to only some patients in the placebo group. These data support examining
mevidalen for symptomatic treatment of patients with
Parkinson disease and
Lewy body dementia.